We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
Read MoreHide Full Article
Key Takeaways
Sanofi's riliprubart received FDA orphan drug status for antibody-mediated rejection in transplants.
The designation provides tax breaks, fee waivers, and 7 years of exclusivity if riliprubart is approved.
Riliprubart is in trials for AMR and CIDP, two serious immune conditions with high unmet treatment needs.
Sanofi (SNY - Free Report) announced that the FDA has granted orphan drug designation to its investigational drug, riliprubart, for the treatment of antibody-mediated rejection (AMR) in solid organ transplantation.
How Does the Orphan Tag Benefit SNY’s Drug Development?
Orphan drug designation is granted by the FDA to therapies intended for the treatment of rare diseases or conditions affecting fewer than 200,000 people in the United States. The goal is to encourage drug development for rare diseases or conditions by offering incentives such as tax credits for clinical testing, waiver of certain fees and most importantly, seven years of market exclusivity upon approval.
For Sanofi, this designation provides riliprubart with important regulatory and financial advantages as it advances through clinical development for AMR in solid organ transplantation — a serious complication where the immune system attacks the donated organ. Currently, there are no FDA-approved therapies for this condition. The designation may help accelerate progress and reduce the development burden as Sanofi works to address this critical unmet need in transplant medicine.
SNY Stock Price Performance
Shares of Sanofi have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
More on Sanofi’s Riliprubart
An investigational IgG4 humanized monoclonal antibody, riliprubart is designed to selectively inhibit activated C1s in the classical complement pathway of the innate immune system.
The drug is currently being evaluated in a mid-stage study for AMR in kidney transplant recipients across two patient groups — those at risk of developing rejection and those already experiencing active AMR.
Apart from AMR, Sanofi is also evaluating riliprubart in two late-stage studies — MOBILIZE and VITALIZE — for a rare neurological disorder called chronic inflammatory demyelinating polyneuropathy (CIDP). While the MOBILIZE study targets patients for whom standard-of-care treatments do not work, the VITALIZE study compares the drug against intravenous immunoglobulin (IVIg).
CIDP is a rare disorder affecting the peripheral nervous system, marked by progressive muscle weakness and sensory loss. Notably, riliprubart has also received orphan drug designation in both the United States and EU for its prospective use in CIDP, highlighting its potential across multiple immune-mediated diseases.
In the past 60 days, loss per share estimates for Amarin’s 2025 have improved from $5.01 to $2.50. Loss per share estimates for 2026 have narrowed from $3.84 to $1.78 during the same period. AMRN stock has surged nearly 65% year to date.
Amarin’s earnings beat estimates in two of the trailing four quarters, met the mark once and missed in the other, delivering an average surprise of 29.11%.
In the past 60 days, loss per share estimates for Immunocore’s 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained nearly 9% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 76.18%.
In the past 60 days, Agenus’ bottom-line estimates for 2025 have significantly improved from a loss of $3.46 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $3.91 to $1.99. AGEN stock has soared 83% so far this year.
Agenus’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
Key Takeaways
Sanofi (SNY - Free Report) announced that the FDA has granted orphan drug designation to its investigational drug, riliprubart, for the treatment of antibody-mediated rejection (AMR) in solid organ transplantation.
How Does the Orphan Tag Benefit SNY’s Drug Development?
Orphan drug designation is granted by the FDA to therapies intended for the treatment of rare diseases or conditions affecting fewer than 200,000 people in the United States. The goal is to encourage drug development for rare diseases or conditions by offering incentives such as tax credits for clinical testing, waiver of certain fees and most importantly, seven years of market exclusivity upon approval.
For Sanofi, this designation provides riliprubart with important regulatory and financial advantages as it advances through clinical development for AMR in solid organ transplantation — a serious complication where the immune system attacks the donated organ. Currently, there are no FDA-approved therapies for this condition. The designation may help accelerate progress and reduce the development burden as Sanofi works to address this critical unmet need in transplant medicine.
SNY Stock Price Performance
Shares of Sanofi have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
More on Sanofi’s Riliprubart
An investigational IgG4 humanized monoclonal antibody, riliprubart is designed to selectively inhibit activated C1s in the classical complement pathway of the innate immune system.
The drug is currently being evaluated in a mid-stage study for AMR in kidney transplant recipients across two patient groups — those at risk of developing rejection and those already experiencing active AMR.
Apart from AMR, Sanofi is also evaluating riliprubart in two late-stage studies — MOBILIZE and VITALIZE — for a rare neurological disorder called chronic inflammatory demyelinating polyneuropathy (CIDP). While the MOBILIZE study targets patients for whom standard-of-care treatments do not work, the VITALIZE study compares the drug against intravenous immunoglobulin (IVIg).
CIDP is a rare disorder affecting the peripheral nervous system, marked by progressive muscle weakness and sensory loss. Notably, riliprubart has also received orphan drug designation in both the United States and EU for its prospective use in CIDP, highlighting its potential across multiple immune-mediated diseases.
SNY’s Zacks Rank
Sanofi currently carries a Zacks Rank #3 (Hold).
Sanofi Price
Sanofi price | Sanofi Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Amarin Corporation (AMRN - Free Report) , Immunocore (IMCR - Free Report) and Agenus (AGEN - Free Report) . While AMRN and IMCR sport a Zacks Rank #1 (Strong Buy) each at present, AGEN carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, loss per share estimates for Amarin’s 2025 have improved from $5.01 to $2.50. Loss per share estimates for 2026 have narrowed from $3.84 to $1.78 during the same period. AMRN stock has surged nearly 65% year to date.
Amarin’s earnings beat estimates in two of the trailing four quarters, met the mark once and missed in the other, delivering an average surprise of 29.11%.
In the past 60 days, loss per share estimates for Immunocore’s 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained nearly 9% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 76.18%.
In the past 60 days, Agenus’ bottom-line estimates for 2025 have significantly improved from a loss of $3.46 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $3.91 to $1.99. AGEN stock has soared 83% so far this year.
Agenus’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%.